Effective neuropathic pain relief through sciatic nerve administration of GAD65-expressing rAAV2

Jaehyung Kim, Sung Jin Kim, Heuiran Lee, JinWoo Chang

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Recently, we demonstrated that the administration of GAD65-expressing rAAV2 to DRG attenuates peripheral neuropathy by inducing GABA release in the spinal cord. However, the direct injection to DRG is invasive and may therefore cause nerve injury and other side effects. To circumvent this surgical intervention, we explored the potential of a much simpler and less invasive route of sciatic nerve administration. Using a neuropathic pain model, we introduced rAAV2-GAD65 through sciatic nerve and examined its therapeutic potency in pain-related behavior tests. Both GFP and GAD65 expression indicated that effective transgene delivery to the DRG can be accomplished via sciatic nerve administration. Equally importantly, the GABA concentration in the spinal cord increased significantly after GAD65 introduction, and pain symptoms were dramatically reduced and persistently controlled. The implication is that the sciatic nerve is a highly promising route for delivering rAAV2 to the DRG, and thus represents a much less invasive, clinically viable gene therapy option.

Original languageEnglish
Pages (from-to)73-78
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume388
Issue number1
DOIs
Publication statusPublished - 2009 Oct 9

Fingerprint

Diagnosis-Related Groups
Neuralgia
Sciatic Nerve
gamma-Aminobutyric Acid
Gene therapy
Spinal Cord
Direct injection
Pain
Peripheral Nervous System Diseases
Transgenes
Genetic Therapy
Injections
Wounds and Injuries
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

@article{a0920d9dceae4e49a0ed9577576ff53b,
title = "Effective neuropathic pain relief through sciatic nerve administration of GAD65-expressing rAAV2",
abstract = "Recently, we demonstrated that the administration of GAD65-expressing rAAV2 to DRG attenuates peripheral neuropathy by inducing GABA release in the spinal cord. However, the direct injection to DRG is invasive and may therefore cause nerve injury and other side effects. To circumvent this surgical intervention, we explored the potential of a much simpler and less invasive route of sciatic nerve administration. Using a neuropathic pain model, we introduced rAAV2-GAD65 through sciatic nerve and examined its therapeutic potency in pain-related behavior tests. Both GFP and GAD65 expression indicated that effective transgene delivery to the DRG can be accomplished via sciatic nerve administration. Equally importantly, the GABA concentration in the spinal cord increased significantly after GAD65 introduction, and pain symptoms were dramatically reduced and persistently controlled. The implication is that the sciatic nerve is a highly promising route for delivering rAAV2 to the DRG, and thus represents a much less invasive, clinically viable gene therapy option.",
author = "Jaehyung Kim and Kim, {Sung Jin} and Heuiran Lee and JinWoo Chang",
year = "2009",
month = "10",
day = "9",
doi = "10.1016/j.bbrc.2009.07.120",
language = "English",
volume = "388",
pages = "73--78",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

Effective neuropathic pain relief through sciatic nerve administration of GAD65-expressing rAAV2. / Kim, Jaehyung; Kim, Sung Jin; Lee, Heuiran; Chang, JinWoo.

In: Biochemical and Biophysical Research Communications, Vol. 388, No. 1, 09.10.2009, p. 73-78.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effective neuropathic pain relief through sciatic nerve administration of GAD65-expressing rAAV2

AU - Kim, Jaehyung

AU - Kim, Sung Jin

AU - Lee, Heuiran

AU - Chang, JinWoo

PY - 2009/10/9

Y1 - 2009/10/9

N2 - Recently, we demonstrated that the administration of GAD65-expressing rAAV2 to DRG attenuates peripheral neuropathy by inducing GABA release in the spinal cord. However, the direct injection to DRG is invasive and may therefore cause nerve injury and other side effects. To circumvent this surgical intervention, we explored the potential of a much simpler and less invasive route of sciatic nerve administration. Using a neuropathic pain model, we introduced rAAV2-GAD65 through sciatic nerve and examined its therapeutic potency in pain-related behavior tests. Both GFP and GAD65 expression indicated that effective transgene delivery to the DRG can be accomplished via sciatic nerve administration. Equally importantly, the GABA concentration in the spinal cord increased significantly after GAD65 introduction, and pain symptoms were dramatically reduced and persistently controlled. The implication is that the sciatic nerve is a highly promising route for delivering rAAV2 to the DRG, and thus represents a much less invasive, clinically viable gene therapy option.

AB - Recently, we demonstrated that the administration of GAD65-expressing rAAV2 to DRG attenuates peripheral neuropathy by inducing GABA release in the spinal cord. However, the direct injection to DRG is invasive and may therefore cause nerve injury and other side effects. To circumvent this surgical intervention, we explored the potential of a much simpler and less invasive route of sciatic nerve administration. Using a neuropathic pain model, we introduced rAAV2-GAD65 through sciatic nerve and examined its therapeutic potency in pain-related behavior tests. Both GFP and GAD65 expression indicated that effective transgene delivery to the DRG can be accomplished via sciatic nerve administration. Equally importantly, the GABA concentration in the spinal cord increased significantly after GAD65 introduction, and pain symptoms were dramatically reduced and persistently controlled. The implication is that the sciatic nerve is a highly promising route for delivering rAAV2 to the DRG, and thus represents a much less invasive, clinically viable gene therapy option.

UR - http://www.scopus.com/inward/record.url?scp=68949150754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949150754&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2009.07.120

DO - 10.1016/j.bbrc.2009.07.120

M3 - Article

C2 - 19643087

AN - SCOPUS:68949150754

VL - 388

SP - 73

EP - 78

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -